Navigation Links
Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Date:3/13/2009

NEW YORK, March 13 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually. Applications will be accepted twice a year, with up to $2.5 million in funding available each spring and another $2.5 million available in the fall.

First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.

Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.

The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly $12.8 million total under the initiative for 24 industry-led projects.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly $140 million in research directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gene Network Sciences Announces Michael Gilman as Board Member
2. Nyenrode Honorary Doctorate for Professor Michael E. Porter
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
5. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decades Real Nutritional Heroes
8. Xceleron Names Michael Butler as President & CEO
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):